CanREValue

CanREValue

Value-based decisions from Real World Evidence

Fall 2022 Newsletter

Canadian Cancer Real-world Evaluation (CCRE) Platform: CADTH Post-Market Drug Evaluation Core Network Partner

The Canadian Cancer Real-world Evaluation (CCRE) Platform has been announced as one of four inaugural Core Network Partners of CADTH's CoLab Network. Core Network Partners will respond to decision-makers' queries, submitted through CADTH-CoLab, about the safety and effectiveness of post-market drug by drawing on their expertise and evidence in the post-market space.

Ontario Health will host the CCRE Platform, with participating sites in Alberta, through O2-Alberta Health Services, and British Columbia, through BC Cancer. CanREValue Principal Investigator Kelvin Chan is the CCRE Platform Lead, with additional Program Leads including Elaine Meertens (Ontario Health), Dr. Jon Irish (Ontario Health), Dr. Kim McGrail (Health Data Research Network Canada), Dr. Mina Tadrous (University of Toronto), Scott Gavura (Ontario Health), Dr. Stuart Peacock (BC Cancer), and Winson Cheung (Alberta Health Services). The CCRE Platform will leverage the CanREValue Collaboration's capabilities in using real-world data to generate RWE that can be used to inform decision-makers regarding the comparative effectiveness and safety of funded cancer therapies at provincial and national levels. The formation of the CCRE Platform will further our commitment to generate and use RWE to support decision-making and promote the sustainability of the Canadian cancer care system.

CADTH's CoLab Network launched September 1, 2022. If you have any questions about the CCRE Platform, please contact Katharina Forster katharina.forster@ontariohealth.ca.

CADTH PMDE CCRE LEADS

Kelvin Chan, MD, FRCPC, MSc, PhD – CCRE Platform Lead, Ontario Health

Kelvin Chan is a Medical Oncologist at the Sunnybrook Odette Cancer Centre, a Professor at the University of Toronto, an Associate Scientist at the Sunnybrook Research Institute, a Scientist with ICES, the Co-Director of ARCC, and the Clinical Lead for Ontario Health's Provincial Drug Reimbursement Programs. Dr Chan's research interests include health services research, health technology assessment, meta-analysis including network meta-analysis, cost-effectiveness analyses, and statistical methods research in health economics.

Elaine Meertens, BScN, MHSc - CCRE Institutional Lead, Ontario Health (Cancer Care Ontario)

Elaine Meertens is Vice President, Cancer Programs at Ontario Health (Cancer Care Ontario) and works in partnership with the Vice President, Clinical, Cancer Programs, Ontario Health (Cancer Care Ontario) to improve the quality, safety and accessibility of evidence-based cancer services. Elaine is an experienced healthcare leader who believes strongly in collaborating with healthcare providers to advance evidence based and person-centered care.

Jonathan C. Irish, MD, MS, FRCSC, FACS - CCRE Institutional Lead, Ontario Health (Cancer Care Ontario)

Jonathan Irish is the Vice-President, Clinical, Cancer Programs at Ontario Health (Cancer Care Ontario) and is also Professor and Division Head of the Head and Neck Oncology and Reconstructive Surgery Division at the University of Toronto. Dr. Irish is a surgical oncologist and reconstructive surgeon with particular expertise in oral cancer, melanoma and skin cancer and thyroid cancer.

Kimberlyn McGrail, MPH, PhD – CCRE Provincial Lead, Health Data Research Network (HDRN) Canada

Kimberlyn McGrail is a Professor in the UBC School of Population and Public Health and Centre for Health Services and Policy Research, Director of Research for UBC Health, and Scientific Director of Population Data BC and HDRN Canada. Dr. McGrail has key research focus in the areas of policy intervention evaluations, the use and cost of health care services, health care financing, aging, equity, and population data science.

Mina Tadrous, PharmD, MS, PhD - CCRE Provincial Lead, University of Toronto

Mina Tadrous is an Assistant Professor at the Leslie Dan Faculty of Pharmacy at University of Toronto leading research focused on evaluating drug policies and post-marketing surveillance of medications. Dr. Tadrous is also a Scientist at Women's College Hospital Institute of Health System Solutions and Virtual Care, and an Investigator with the Ontario Drug Policy Research Network and an adjunct scientist at ICES. Dr. Tadrous has additional research interests in leveraging big data sets to help policymakers and health care practitioners make evidence-based decisions regarding real-world medication safety, effectiveness, and optimal use.

Scott Gavura, BScPhm, MBA, RPh – CCRE Institutional Lead, Ontario Health

Scott Gavura is the Director of Provincial Drug Reimbursement Programs at Ontario Health. Scott is a pharmacist with more than two decades of experience improving the quality and use of medicines, supporting pharmacists as health care providers, and promoting informed patient decision-making, with a specialization is in public drug reimbursement policy, and in reimbursement program delivery. Scott is currently the Vice-Chair of CADTH's Provincial Advisory Group, which provides strategic advice to the CADTH Pharmaceutical Advisory Committee about operational issues, as well as to inform strategic and policy direction.

Stuart Peacock, MSc DPhil – CCRE Provincial Lead, BC Cancer

Stuart Peacock is a Distinguished Scientist at BC Cancer, and holds the Leslie Diamond Chair in Cancer Survivorship in the Faculty of Health Sciences at Simon Fraser University. He is Co-Director of ARCC and a Fellow of the Canadian Academy of Health Sciences. Dr. Peacock has research interests in developing more effective cancer services, making health system funding decisions fairer and more transparent, and improving the quality of life of cancer patients and survivors.

Winson Cheung, MD, MPH – CCRE Provincial Lead, Alberta Health Services

Winson Cheung is a Medical Oncologist, the Principal Director of Oncology Outcomes (O2), a Professor in the Departments of Oncology, Medicine and Community Health Services at the University of Calgary, and the Provincial Director and Chair of the Health Services Researcher and RWE Generation Program at Cancer Control Alberta. Dr. Cheung has research interests in using big data for health services and outcomes research as well as generating RWE across all tumor sites.

WORKING GROUP UPDATES AND NEXT STEPS:

Working Group	Updates & Next Steps
Planning and Drug Selection	**Updates:** • Fourth MCDA Soft Launch held on June 23ʳᵈ, 2022. **Next Steps:** • Continue assessing the MCDA rating tool. Next soft launch will take place during Fall 2022
Data	**Next Steps:** • Plan for next interprovincial meeting • Continue with real-world analysis in 9 provinces
Methods	**Next Steps:** • Consult and discuss appropriate methodology for next identified outcome measure • Continue support of Data WG on 9 province analysis
Reassessment and Uptake	**Updates:** • Exploring the opportunities to operationalize Step 4 through a demonstration project. **Next Steps:** • Continue working with WG members and relevant stakeholders to further operationalize Step 4 through a demonstration project.
Engagement	**Updates:** • Submitted manuscript of patient engagement experience **Next Steps:** • Plan for secondary industry engagement opportunity in the Fall

Recent Publications/Presentations:

Evans WK, Takhar P, McDonald V, et al. Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned. *Current Oncology.* 2022 29(8) 5616-5626.

Evans WK, Takhar P, McDonald V, et al. Engaging Patients in the CanREValue Initiative: Processes and Lessons Learned. 2022 ARCC Conference (Poster Presentation), May 16-17, 2022.

Muñoz C, Dai WF, Beca J, et al. CanREValue Data Working Group Members, Chan, KKW. What's in our way?: The challenges and recommendations of using real-world oncology data to generate real-world evidence for drug funding decisions. 2022 ARCC Conference (On-demand Presentation), May 16-17, 2022.